EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Neuroinflammation and insulin resistance in major depression and bipolar disorder: Implications for clinical trials evaluating immunometabolic targeted therapies

Folkert H van Bruggen, Roger S McIntyre

Brain, Behavior, & Immunity - Health · 2026-02 · 51 · 101166

DOI: 10.1016/j.bbih.2025.101166 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Brain, Behavior, & Immunity - Health, 2026-02. Verfasst von Folkert H van Bruggen und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Primary and Long-Term Care, University Medical Centre Groningen, University of Groningen, P.O. Box 196, 9700 AD, Groningen, the Netherl…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AbbVie, Canadian Institutes of Health Research, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bipolar disorder (BD) and major depressive disorder (MDD) are highly prevalent, disabling psychiatric illnesses marked by substantial heterogeneity and frequent metabolic and inflammatory comorbidities. Growing evidence implicates low-grade inflammation, immune dysregulation, and insulin resistance (IR) in the pathophysiology, progression, and treatment response of mood disorders. While numerous clinical trials have investigated immunometabolic targeted interventions, outcomes have been inconsistent, due to limited stratification of participants based on underlying biology. This perspective paper aims to identify practical biomarkers and biosignatures to guide patient selection and optimize immunometabolic trial design. We summarize evidence linking neuroinflammation and IR to illness burden, discuss clinical trials targeting these mechanisms, and highlight emerging markers, including extracellular vesicles, monocyte gene expression profiles, and neuron-derived vesicle signatures of IR. No single validated biomarker for identification of immunometabolic phenotype currently exists, but multimodal biosignatures combining genetic, epigenetic, proteomic, and clinical features offer a pragmatic empirical path forward. Integrating these markers with advanced analytic approaches, such as machine learning, holds promise for identifying biologically coherent subgroups most likely to benefit from targeted immunometabolic interventions, accelerating precision medicine for BD and MDD.

Schlagwörter

Stichwörter der Autor:innen

Bipolar disorderImmunometabolic biomarkersInsulin resistanceMajor depressive disorderNeuroinflammation

Autor:innen und Institutionen

  • Department of Primary and Long-Term Care, University Medical Centre Groningen, University of Groningen, P.O. Box 196, 9700 AD, Groningen, the Netherlands.
  • Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
  • Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada.

Förderung

  • AbbVie
  • Canadian Institutes of Health Research
  • National Natural Science Foundation of China
  • Life Sciences, University of California, Los Angeles
  • Milken Institute
  • Global Alliance for Chronic Diseases

Zitieren

APA

van Bruggen, F. H., & McIntyre, R. S. (2026). Neuroinflammation and insulin resistance in major depression and bipolar disorder: Implications for clinical trials evaluating immunometabolic targeted therapies. Brain, Behavior, & Immunity - Health, 51, 101166. https://doi.org/10.1016/j.bbih.2025.101166

Vancouver

van Bruggen FH, McIntyre RS. Neuroinflammation and insulin resistance in major depression and bipolar disorder: Implications for clinical trials evaluating immunometabolic targeted therapies. Brain, Behavior, & Immunity - Health. 2026;51:101166. doi:10.1016/j.bbih.2025.101166

BibTeX
@article{vanBruggen2026,
  author = {van Bruggen, Folkert H and McIntyre, Roger S},
  title = {Neuroinflammation and insulin resistance in major depression and bipolar disorder: Implications for clinical trials evaluating immunometabolic targeted therapies},
  journal = {Brain, Behavior, & Immunity - Health},
  year = {2026},
  volume = {51},
  pages = {101166},
  doi = {10.1016/j.bbih.2025.101166}
}
Kostenlos starten →